Status: Recruiting
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Participants needed: 116
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan YZY Biopharma Co., Ltd.Updated: Jul 8, 2026Locations: 1
Eligibility criteria
Aged >18 years and ≤ 75 years, male or female. [+6]
Subjects with recurrent pleural effusion within 4 weeks after the last intrathor... [+16]